Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Mar 28, 2023 12:58pm
132 Views
Post# 35364899

RE:Are the executives and the board that dumb and unware?

RE:Are the executives and the board that dumb and unware?My opinion on NASH is the company pulled off a heroic feat in getting data that was not the data which was needed/appropriate and still convincing the FDA to approve a phase IIb/III trial despite that. I suspect the problem they face in getting a partner is the data is not "clean"so partners are reticent.  Management did a great job of taking something that was not appropriate and making it relevant. They should be applauded for that. That they have not yet been bale to get it over the final hump to a partenrship and a trial that has started should not take away from their good efforts to get it to that implausible point. Since they have not been able to secure a partnership, I am assuming the lack of clean phase II data is a stumbling block for partners or it has something to do with patents or the mode of administration. 

Joemare wrote: Biggest flop is lack of NASH roadmap and partnership.  Wasted three freakin' years with solid p.II data.
Fire the coach. Fire the GM. Fire the VPs, Fire the President. Put a sign up for sale. These guys are dumb and dumber by the day.


<< Previous
Bullboard Posts
Next >>